Filing Flows › Fulgent Genetics (FLGT) › Guidance & outlook
Fulgent Genetics (FLGT) guidance and outlook
Fulgent Genetics (FLGT) initiated its guidance on Nov 5, 2026: Revenue $330M–$340M for FY2026. Fulgent Genetics' 10-Q filed Nov 5, 2026 makes 22 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $330M–$340M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
- We expect the additional impact of the Bako Acquisition on our consolidated results of operations, including revenue, cost of revenue, and operating expenses, to be reflected in future periods.
- Ultimately, we may not realize the anticipated benefits of this transaction.
- As previously disclosed in our 2025 Annual Report, we expect revenues for our largest customer to continue to decline in 2026 as this customer continues to increase the performance of tests internally.
- To reduce this revenue risk, we will focus on developing existing customers and increasing the number of customers and thereby reducing the concentration and on successfully integrating our acquired businesses.
- We believe the factors that will affect our ability to grow these revenue streams are 1) the average price point we offer and the reimbursement rate from insurance payors; 2) the concentration of our payor base; 3) the competitive advantage we have due to our broad and flexible test menu, detection rate, and turnaround times; and 4) growth in size of an addressable market.
- Going forward, we will strive to maintain this competitive advantage and emphasize this in our marketing efforts to grow our testing revenue.
- As previously disclosed, we expect revenues for this customer to continue to decline in 2026 as this customer continues to transition the performance of tests internally.
- As the remaining customizations are completed and integrated across our revenue cycle, we expect our collection rate, and correspondingly our gross margin, to improve, though we cannot predict the exact timing of that improvement.
- Expenses for our therapeutic development segment will be influenced by our ability to progress our therapeutic candidates through development with the Food and Drug Administration, or the FDA, the timing of which can be uncertain and delayed due to a variety of factors beyond our control, including staff reductions at the FDA, which may affect the FDA’s ability to provide any required approvals or review in a…
- We expect our research and development expenses to increase when we continue our development efforts.
- Looking ahead, we expect research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other pre-clinical studies.
Fulgent Genetics' latest quarter
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
Questions
Did Fulgent Genetics raise or lower its guidance?
Fulgent Genetics (FLGT) initiated its guidance on Nov 5, 2026: Revenue $330M–$340M for FY2026.
What does Fulgent Genetics expect?
Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. We expect the additional impact of the Bako Acquisition on our consolidated results of operations, including revenue, cost of revenue, and operating expenses, to be reflected in future periods. Ultimately, we may not realize the anticipated benefits of this transaction.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.